Zalunfiban - Celecor Therapeutics
Alternative Names: Disaggpro; RUC 4; RUC-4 acetate; Zalunfiban acetate - Celecor TherapeuticsLatest Information Update: 29 Jun 2026
At a glance
- Originator Rockefeller University
- Developer CeleCor Therapeutics
- Class Acetamides; Anti-ischaemics; Antiplatelets; Piperazines; Pyrazoles; Pyridines; Pyrimidines; Small molecules; Thiadiazoles; Vascular disorder therapies
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Myocardial infarction
- No development reported Coronary artery disease